Clover Health Investments, Corp. /De (CLOV): who owns it and who trades it
As of Nov 16, 2026, CLOV insiders reported 41 open-market sales worth $8.7M and no purchases in the last 12 months, with 88% of the sale value made under pre-set 10b5-1 plans. The largest seller was Andrew Toy (CEO), with $4M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Clover Health Investments
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns CLOV
225 funds and institutions reported CLOV shares worth $789M at the end of Q2 2026. The largest holder is BlackRock, Inc. with $184M.
10 largest owners, by value
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 35.11M | – | $184M | +10% |
| Vanguard Capital Management LLC | 18.04M | – | $94.5M | +6% |
| Geode Capital Management, LLC | 10.85M | – | $56.8M | +8% |
| State Street Corp | 10.18M | – | $53.3M | +6% |
| Nuveen, LLC | 6.29M | – | $33M | +573% |
| Charles Schwab Investment Management Inc | 5.52M | – | $28.9M | +4% |
| Sixth Street Partners Management Company, L.P. | 5.52M | – | $28.9M | – |
| Vanguard Portfolio Management LLC | 4.47M | – | $23.4M | +21% |
| Northern Trust Corp | 3.77M | – | $19.8M | +14% |
| PNC Financial Services Group, Inc. | 3.56M | – | $18.7M | -5% |
| Dimensional Fund Advisors LP | 3.15M | – | $16.5M | -8% |
| Vanguard Fiduciary Trust Co | 2.92M | – | $15.3M | +4% |
| Renaissance Technologies LLC | 2.81M | – | $14.7M | -17% |
| Morgan Stanley | 2.29M | – | $12M | +5% |
| Citadel Advisors LLC | 2.16M | – | $11.3M | +15% |
| D. E. Shaw & Co., Inc. | 1.97M | – | $10.3M | +2060% |
| Marshall Wace, LLP | 1.56M | – | $8.2M | – |
| Invesco Ltd. | 1.34M | – | $7M | +30% |
| GMT Capital Corp | 1.31M | – | $6.8M | No change |
| Mackenzie Financial Corp | 1.30M | – | $6.8M | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, CLOV insiders reported $0 of open-market purchases and $8.7M of sales. 88% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 20, 2026 | Karen Soares | Chief Legal Officer | Sale plan | 19,275 | $4.66 | $89.8K | Form 4 |
| Oct 19, 2026 | Jamie L. Reynoso | CEO | Sale plan | 4,066 | $4.41 | $17.9K | Form 4 |
| Oct 15, 2026 | Jamie L. Reynoso | CEO | Sale plan | 18,273 | $4.68 | $85.5K | Form 4 |
| Oct 15, 2026 | Conrad Wai | CEO | Sale plan | 23,627 | $4.68 | $111K | Form 4 |
| Oct 15, 2026 | Joseph Clay Thornton | CFO | Sale plan | 4,591 | $4.68 | $21.5K | Form 4 |
| Oct 15, 2026 | Karen Soares | Chief Legal Officer | Sale plan | 14,673 | $4.68 | $68.7K | Form 4 |
| Oct 15, 2026 | Andrew Toy | CEO | Sale plan | 62,176 | $4.68 | $291K | Form 4 |
| Oct 7, 2026 | Jamie L. Reynoso | CEO | Sale plan | 2,006 | $4.63 | $9.3K | Form 4 |
| Oct 5, 2026 | Jamie L. Reynoso | CEO | Sale plan | 8,750 | $4.42 | $38.7K | Form 4 |
| Oct 1, 2026 | Andrew Toy | CEO | Sale plan | 318,806 | $4.19 | $1.3M | Form 4 |
| Sep 17, 2026 | Jamie L. Reynoso | CEO | Sale plan | 1,921 | $4.56 | $8.8K | Form 4 |
| Sep 16, 2026 | Joseph Frank Oldakowski | Vice president | Sale plan | 3,170 | $4.64 | $14.7K | Form 4 |
| Sep 15, 2026 | Conrad Wai | CEO | Sale plan | 300,000 | $4.72 | $1.4M | Form 4 |
| Sep 15, 2026 | Karen Soares | Chief Legal Officer | Sale plan | 6,846 | $4.78 | $32.7K | Form 4 |
| Sep 15, 2026 | Jamie L. Reynoso | CEO | Sale plan | 9,273 | $4.78 | $44.3K | Form 4 |
| Sep 14, 2026 | Joseph Frank Oldakowski | Vice president | Sale | 20,000 | $5.16 | $103K | Form 4 |
| Aug 17, 2026 | Joseph Clay Thornton | CFO | Sale plan | 17,775 | $4.39 | $78K | Form 4 |
| Aug 10, 2026 | Andrew Toy | CEO | Sale plan | 87,798 | $4.65 | $408K | Form 4 |
| Jul 20, 2026 | Karen Soares | Chief Legal Officer | Sale plan | 51,700 | $4.51 | $233K | Form 4 |
| Jul 17, 2026 | Jamie L. Reynoso | CEO | Sale plan | 4,839 | $4.53 | $21.9K | Form 4 |
| Jul 15, 2026 | Andrew Toy | CEO | Sale plan | 62,711 | $4.67 | $293K | Form 4 |
| Jul 15, 2026 | Conrad Wai | CEO | Sale plan | 24,215 | $4.67 | $113K | Form 4 |
| Jul 15, 2026 | Jamie L. Reynoso | CEO | Sale plan | 13,119 | $4.67 | $61.3K | Form 4 |
| Jul 15, 2026 | Karen Soares | Chief Legal Officer | Sale plan | 10,519 | $4.67 | $49.1K | Form 4 |
| Jul 15, 2026 | Joseph Clay Thornton | CFO | Sale plan | 4,630 | $4.67 | $21.6K | Form 4 |
| Jul 8, 2026 | Jamie L. Reynoso | CEO | Sale plan | 2,384 | $4.68 | $11.2K | Form 4 |
| Jul 6, 2026 | Jamie L. Reynoso | CEO | Sale plan | 6,229 | $5.26 | $32.8K | Form 4 |
| Jul 1, 2026 | Andrew Toy | CEO | Sale plan | 313,476 | $5.32 | $1.7M | Form 4 |
| Jun 17, 2026 | Jamie L. Reynoso | CEO | Sale plan | 2,360 | $4.78 | $11.3K | Form 4 |
| Jun 16, 2026 | Joseph Frank Oldakowski | Vice president | Sale plan | 12,102 | $4.86 | $58.8K | Form 4 |
| Jun 15, 2026 | Karen Soares | Chief Legal Officer | Sale plan | 4,681 | $4.61 | $21.6K | Form 4 |
| Jun 15, 2026 | Jamie L. Reynoso | CEO | Sale plan | 6,350 | $4.61 | $29.3K | Form 4 |
| Jun 11, 2026 | Jamie L. Reynoso | CEO | Sale plan | 7,289 | $4.91 | $35.8K | Form 4 |
| May 28, 2026 | Conrad Wai | CEO | Sale plan | 220,426 | $3.99 | $879K | Form 4 |
| May 18, 2026 | Carladenise Armbrister Edwards | Director | Sale | 67,160 | $3.42 | $230K | Form 4 |
| May 13, 2026 | Brady Patrick Priest | CEO | Sale | 98,039 | $3.52 | $345K | Form 4 |
| Mar 18, 2026 | Jamie L. Reynoso | CEO | Sale plan | 5,833 | $1.91 | $11.1K | Form 4 |
| Mar 4, 2026 | Brady Patrick Priest | CEO | Sale | 175,000 | $2.17 | $380K | Form 4 |
| Jan 20, 2026 | Jamie L. Reynoso | CEO | Sale plan | 4,597 | $2.58 | $11.9K | Form 4 |
| Jan 7, 2026 | Jamie L. Reynoso | CEO | Sale plan | 2,102 | $2.53 | $5.3K | Form 4 |
| Dec 18, 2025 | Jamie L. Reynoso | CEO | Sale plan | 4,913 | $2.61 | $12.8K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Andrew Toy | Chief Executive Officer, Director | – | $4M | Oct 15, 2026 |
| Conrad Wai | CEO, Counterpart Health | – | $2.5M | Oct 15, 2026 |
| Brady Patrick Priest | CEO of Home Care | – | $725K | May 13, 2026 |
| Karen Soares | Chief Legal Officer | – | $495K | Oct 20, 2026 |
| Jamie L. Reynoso | CEO, Medicare Advantage | – | $449K | Oct 19, 2026 |
| Carladenise Armbrister Edwards | Director | – | $230K | May 18, 2026 |
| Joseph Frank Oldakowski | VP OF FINANCE AND CONTROLLER | – | $177K | Sep 16, 2026 |
| Joseph Clay Thornton | Interim CFO | – | $121K | Oct 15, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
CLOV short interest
23.03M CLOV shares are sold short. Over the last 12 reports the number of shares short went down 38%.
As of Oct 30, 2026, 23.03M CLOV shares were sold short, down 11.3% from the report before. At the average daily volume of 3.42M shares, buying them all back would take about 6.7 trading days (days to cover).
Shares short
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 23.03M | – | -11% | 3.42M | 6.7 |
| Oct 15, 2026 | 25.95M | – | +13% | 4.86M | 5.3 |
| Sep 30, 2026 | 22.90M | – | -2% | 3.63M | 6.3 |
| Sep 15, 2026 | 23.45M | – | -1% | 4.53M | 5.2 |
| Aug 31, 2026 | 23.68M | – | -9% | 3.45M | 6.9 |
| Aug 14, 2026 | 26.14M | – | -7% | 5.25M | 5.0 |
| Jul 31, 2026 | 28.24M | – | -2% | 3.93M | 7.2 |
| Jul 15, 2026 | 28.75M | – | +30% | 5.88M | 4.9 |
| Jun 30, 2026 | 22.18M | – | -11% | 7.92M | 2.8 |
| Jun 15, 2026 | 24.85M | – | -13% | 9.96M | 2.5 |
| May 29, 2026 | 28.60M | – | -24% | 8.25M | 3.5 |
| May 15, 2026 | 37.39M | – | -4% | 8.13M | 4.6 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Clover Health Investments company events
Clover Health Investments filed 19 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership). The latest was on Nov 4, 2026.
- Nov 4, 2026LeadershipThe Board of Directors of the Company appointed Joseph Clay Thornton, age 37, the Company’s Interim Chief Financial Officer and principal financial officer, to serve as the Company’s Chief Financial Officer on a permanent basis, and appointed Joseph Frank Oldakowski, age 44, the Company’s Vice… Filing
- Oct 9, 2026AnnouncementShared information with investors. Filing
- Sep 25, 2026LeadershipAmended an earlier report. The Board of Directors of Clover Health Investments, Corp. appointed Senator Robert G. Torricelli to serve as a Class I director of the Board and Dr. Brian J. Miller, M.D., M.B.A., M.P.H. to serve as a Class III director of the Board. Filing
- Sep 24, 2026LeadershipThe Board of Directors of Clover Health Investments, Corp. appointed Senator Robert G. Torricelli to serve as a Class I director of the Board and Dr. Brian J. Miller, M.D., M.B.A., M.P.H. to serve as a Class III director of the Board. Filing
- Aug 20, 2026AnnouncementShared information with investors. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jul 17, 2026AnnouncementClover Health Investments, Corp. became aware of anomalous login activity on certain of its information systems. Filing
- Jun 18, 2026AnnouncementAs previously disclosed, on June 9, 2026, the Centers for Medicare & Medicaid Services informed Clover Health Investments, Corp. that, consistent with a court judgment in Clover Insurance Co. V. HHS, Civ. Filing
- Jun 16, 2026LeadershipBrady Priest notified Clover Health Investments, Corp. of his decision to step down from his position as Chief Executive Officer of Clover Care Services, the Company’s home-care business, effective as of July 3, 2026. Filing
- Jun 12, 2026VoteReported shareholder vote results. Filing
- Jun 10, 2026AnnouncementThe United States District Court for the Southern District of Georgia entered final judgment in Clover Insurance Co. v. Filing
- May 18, 2026AnnouncementShared information with investors. Filing
- May 6, 2026ResultsReleased financial results. Filing
- Apr 1, 2026LeadershipThe board of directors of Clover Health Investments, Corp. approved a transition of the Chief Financial Officer role. Filing
- Mar 6, 2026AnnouncementAmended an earlier report. Shared information with investors. Filing
- Mar 6, 2026AnnouncementShared information with investors. Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Jan 14, 2026AnnouncementShared information with investors. Filing
- Dec 10, 2025AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Clover Health Investments financials
Famous investors that hold CLOV
4 of the 50 well-known investors we track reported holding CLOV in their latest 13F filing. The largest position is Jim Simons's, worth $19.6M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 4.55M | $19.6M | 0.0% | +62% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 2.82M | $12.1M | 0.0% | +30% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 2.15M | $9.3M | 0.0% | +101% |
| Israel Englander · Millennium Management | Q3 2026 | 231,382 | $997K | 0.0% | -79% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Clover Health Investments, Corp. /De (CLOV) stock
Who owns the most CLOV stock?
The largest reported owner of Clover Health Investments, Corp. /De (CLOV) is BlackRock, Inc.. In total, 225 funds and institutions reported holding CLOV at the end of Q2 2026. See the largest owners.
Are CLOV insiders buying or selling?
In the last 12 months, CLOV insiders reported no open-market purchases and 41 sales worth $8.7M. The latest trade was on Oct 20, 2026. See every trade.
What is the short interest in CLOV?
As of Oct 30, 2026, 23.03M CLOV shares were sold short, down 11.3% from the report before. At the average daily volume of 3.42M shares, buying them all back would take about 6.7 trading days (days to cover). See the history.
Which famous investors hold CLOV?
4 of the 50 well-known investors we track reported CLOV in their latest 13F filing, including Jim Simons, Ken Griffin, Steve Cohen. The largest position is worth $19.6M. See all holders.
Executive pay
Clover Health Investments's chief executive was paid a total of $1.3M for the year ended Dec 31, 2025, down 86% from $9.5M the year before. In the last 12 months, Clover Health Investments's executives and directors bought no stock on the open market and sold $8.7M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.